Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes
Jingjing Chen, Yalei Li, Jie Zhang, et al.
European Journal of Medicinal Chemistry (2020) Vol. 209, pp. 112868-112868
Closed Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

Therapeutic potential of pyrrole and pyrrolidine analogs: an update
N. Jeelan Basha, S. M. Basavarajaiah, K. Shyamsunder
Molecular Diversity (2022) Vol. 26, Iss. 5, pp. 2915-2937
Open Access | Times Cited: 119
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity
Xin-Hui Zhang, Qin-Ma, Hui-Pan Wu, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 3, pp. 1362-1391
Closed Access | Times Cited: 106
Annual review of PROTAC degraders as anticancer agents in 2022
Xiao Wang, Zhao-Long Qin, Na Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116166-116166
Closed Access | Times Cited: 54
Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist
Xiangqian Li, Xiaowei Li, Fang Liu, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 15, pp. 10581-10605
Closed Access | Times Cited: 101
Bromodomain inhibitors and therapeutic applications
G. Bharath Kumar, Ming‐Ming Zhou
Current Opinion in Chemical Biology (2023) Vol. 75, pp. 102323-102323
Open Access | Times Cited: 30
Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy
Jing Ye, Junhao Wu, Bo Liu
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 3, pp. 188866-188866
Closed Access | Times Cited: 27
Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives
Lu Feng, Guan Wang, Yi Chen, et al.
Medicinal Research Reviews (2021) Vol. 42, Iss. 2, pp. 710-743
Open Access | Times Cited: 42
Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development
Juncheng Chen, Pan Tang, Yuxi Wang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 7, pp. 5184-5211
Closed Access | Times Cited: 36
A Comprehensive Review of BET Protein Biochemistry, Physiology, and Pathological Roles
Hafiz Akbar Ali, Yalan Li, Akram Hafiz Muhammad Bilal, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 31
A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy
Weixin Zhang, Jiao Huang, Xin-Yi Tian, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115673-115673
Closed Access | Times Cited: 22
Targeting bromodomain-containing proteins: research advances of drug discovery
Zhaoping Pan, Yuxi Zhao, Xiaoyun Wang, et al.
Molecular Biomedicine (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 18
Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization
Nicolas Bauer, Dimitrios-Ilias Balourdas, Joel R. Schneider, et al.
ACS Chemical Biology (2024) Vol. 19, Iss. 2, pp. 266-279
Open Access | Times Cited: 6
Advances in dual-targeting inhibitors of HDAC6 for cancer treatment
Zhicheng Gu, Shuxian Lin, Junhui Yu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116571-116571
Closed Access | Times Cited: 6
CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition
Arshdeep Singh, Ting-Yu Chang, Navdeep Kaur, et al.
European Journal of Medicinal Chemistry (2021) Vol. 215, pp. 113169-113169
Closed Access | Times Cited: 29
Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy
Ying‐Chao Duan, Shaojie Zhang, Xiaojing Shi, et al.
European Journal of Medicinal Chemistry (2021) Vol. 222, pp. 113588-113588
Closed Access | Times Cited: 27
Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer
Milan Beljkaš, Aleksandra Ilić, Alen Cebzan, et al.
Pharmaceutics (2023) Vol. 15, Iss. 11, pp. 2581-2581
Open Access | Times Cited: 11
Defeating MYC with drug combinations or dual-targeting drugs
Philip E. Thompson, Jake Shortt
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 6, pp. 490-502
Closed Access | Times Cited: 4
Semisynthesis of Glycosmis pentaphylla Alkaloid Derivatives: Pyranoacridone-Hydroxamic Acid Cytotoxic Conjugates with HDAC and Topoisomerase II α Dual Inhibitory Activity
Parusu Kavya Teja, Bao Q. Ly, Vinal Upadhyay, et al.
Journal of Natural Products (2025)
Closed Access
Discovery, optimization and biological evaluation of chromone derivatives as novel BRD4 inhibitors
Zhao‐Tong Jia, Youyong Li, Wei Shi, et al.
Medicinal Chemistry Research (2025)
Closed Access
Epigenetic Target Fishing with Accurate Machine Learning Models
Norberto Sánchez‐Cruz, José L. Medina‐Franco
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 12, pp. 8208-8220
Open Access | Times Cited: 25
Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects
Jinxiao Ru, Yuxi Wang, Zijia Li, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115800-115800
Closed Access | Times Cited: 10
Research progress of multi-target HDAC inhibitors blocking the BRD4-LIFR-JAK1-STAT3 signaling pathway in the treatment of cancer
Shuting Jia, Yuye Jia, Sufang Liang, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 110, pp. 117827-117827
Closed Access | Times Cited: 3
Small molecules targeting HDAC6 for cancer treatment: Current progress and novel strategies
Ziqian Huang, Ling Li, Binbin Cheng, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117218-117218
Open Access | Times Cited: 3
Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: Current situation and future directions
Wenke Jin, Huidan Tan, Junhao Wu, et al.
Drug Discovery Today (2021) Vol. 27, Iss. 1, pp. 246-256
Closed Access | Times Cited: 23
Bromodomain and extra-terminal inhibitors—A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children—ACCELERATE
Andrew D.J. Pearson, Steven G. DuBois, Victoria Buenger, et al.
European Journal of Cancer (2021) Vol. 146, pp. 115-124
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top